NewishT
/ Newish Technology
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 28, 2023
NewishT Cell Therapy for HCC With High Risk of Recurrence After Radical Resection
(clinicaltrials.gov)
- P1 | N=26 | Recruiting | Sponsor: Newish Technology (Beijing) Co., Ltd. | Trial completion date: Jun 2024 ➔ Dec 2024 | Trial primary completion date: Dec 2023 ➔ Jun 2024
Trial completion date • Trial primary completion date • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1